| Dynavax's Chronic Kidney Disease Study Confirms HEPLISAV's Enhanced ... - MarketWatch (press release) |
|
|
MarketWatch (press release)In 2006, there were approximately 750000 end-stage renal disease (ESRD) patients in the United States and the five major European markets; ... read more |